Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

A small subset of patients with nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHLs) develop a non-Hodgkin lymphoma either concurrently or subsequently, usuallyT-cell/histiocyte-rich B-cell lymphomas (T/HRBCL), which are subtypes of diffuse large B-cell lymphomas (DLBCL). The standard treatmen...

Full description

Bibliographic Details
Main Authors: Hyung-Chul Park, Sung-Hoon Jung, Jae-Sook Ahn, Mi-Young Kim, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee
Format: Article
Language:English
Published: Karger Publishers 2012-08-01
Series:Case Reports in Oncology
Subjects:
Transformation
Nodular lymphocyte-predominant Hodgkin’s lymphoma
T-cell/histiocyte-rich B-cell lymphoma
Chemotherapy
Online Access:http://www.karger.com/Article/FullText/341562

Internet

http://www.karger.com/Article/FullText/341562

Similar Items